Skip to main content
SpringerLink
Log in

Risikoadaptierte multimodale gynäkozytologische Krebsvorsorge

Pap-Test der Zukunft?

Risk-adapted multimodal laboratory cervical screening – Pap test of the future?

  • Schwerpunkt: Zytopathologie
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Das Ziel der gynäkologischen Vorsorgezytologie ist es, Mortalität und Inzidenz des Zervixkarzinoms zu senken. Die Evidenzlage spricht dafür, dass dieses Ziel durch zytologiebasierte Vorsorgeprogramme erreicht werden kann. Dieser Artikel gibt einen praxisbezogenen Überblick konventioneller, neuerer adjuvanter und experimenteller Methoden für die gynäkologische Vorsorgezytologie. Hier werden mögliche zukünftige Entwicklungen einer optimierten Krebsvorsorge durch risikoadaptierte multimodale Protokolle beschrieben, die eine präzisere Diagnose bestehender zervikaler Läsionen und eine prognostische Aussage über ihren wahrscheinlichen Ablauf ermöglichen.

Abstract

The objective of screening for cervical cancer is to reduce mortality and incidence of the disease. To date there is extensive and strong evidence that this can be achieved by cytology-based screening programs, which continue to be the mainstay of cervical prevention worldwide despite their inherent methodological limitations. This article presents a review on the utility of conventional, ancillary and experimental methods for cervical screening both as single tests and test combinations, and describes possible future directions for enhanced screening accuracy using risk-adapted protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Advisory Committee on Cancer Prevention (2000) Recommendations on cancer screening in the European Union. Eur J Cancer 36: 1473–1478

    Article  Google Scholar 

  2. Arbyn M, Buntinx F, Van Ranst M et al. (2004) Virologic versus cytologic trial of women with equivocal Pap smears: a metaanalysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96: 280–293

    Article  PubMed  Google Scholar 

  3. Becker N (2003) Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 129: 691–702

    Article  PubMed  Google Scholar 

  4. Bibbo M, Dytch HE, Alenghat E et al. (1989) DNA ploidy profiles as prognostic indicators in CIN lesions. Am J Clin Pathol 92: 261–265

    PubMed  CAS  Google Scholar 

  5. Bollmann M, Bánkfalvi A, Trosic A et al. (2005) Can we detect cervical human papillomavirus (HPV)-infection by cytomorphology alone? Diagnostic value of non-classic cytological signs of HPV effect in minimally abnormal Pap tests. Cytopathology 16: 13–21

    Article  PubMed  CAS  Google Scholar 

  6. Bollmann R, Bánkfalvi A, Griefingholt H et al. (2005) Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: Results from 31031 women from the Bonn-region in West Germany. Oncol Rep 13: 915–922

    PubMed  CAS  Google Scholar 

  7. Bollmann R, Mehes G, Speich N et al. (2005) Aberrant highly hyperdiploid cells in HPV-positive abnormal cytological samples are associated with progressive lesions of the uterine cervix. Cancer Cytopathol 105: 96–100

    Google Scholar 

  8. Bollmann R, Mehes G, Torka R et al. (2003) Determination of features indicating progression in atypical squamous cells with undetermined significance: Human papillomavirus typing and DNA ploidy analysis from liquid-based cytologic samples. Cancer Cytopathol 99: 113–117

    Google Scholar 

  9. Bollmann R, Mehes G, Torka R et al. (2003) Human papillomavirus typing and DNA ploidy determination of squamous intraepithelial lesions in liquid-based cytologic samples. Cancer Cytopathol 99: 57–62

    Google Scholar 

  10. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481–488

    Article  PubMed  CAS  Google Scholar 

  11. Cuzick J, Szarewski A, Cubie H et al. (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362: 1871–1876

    Article  PubMed  CAS  Google Scholar 

  12. Ferreccio C, Bratti MC, Sherman ME et al. (2003) A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 12: 815–823

    PubMed  Google Scholar 

  13. Grote HJ, Nyuyen HVQ, Leick AG, Böcking A (2004) Identification of progressive cervical epithelial cell abnormalities using DNA image cytometry. Cancer Cytopathol 102: 373–379

    Google Scholar 

  14. Gustafsson L, Ponten J, Zack M, Adami HO (1997) International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8: 55–63

    Article  Google Scholar 

  15. Ho GY, Burk RD, Klein S et al. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365–1371

    Article  PubMed  CAS  Google Scholar 

  16. Kjaer SK, Brule AJ van den, Paul G et al. (2002) Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. BMJ 325: 1–7

    Article  Google Scholar 

  17. Klaes R, Friedrich T, Spitkovsky D et al. (2001) Overexpression of P16INK4a as specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92: 276–284

    Article  PubMed  CAS  Google Scholar 

  18. Kruse AJ, Skaland I, Janssen EA et al. (2004) Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: Role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol 23: 100–109

    Article  PubMed  Google Scholar 

  19. Lie AK, Risberg B, Borge B et al. (2005) DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 97: 908–915

    Article  PubMed  CAS  Google Scholar 

  20. Melsheimer P, Vinokurova S, Wentzensen N et al. (2004) DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res 10: 3059–3063

    Article  PubMed  CAS  Google Scholar 

  21. Nanda K, McCrory DC, Myers ER et al. (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132: 810–819

    PubMed  CAS  Google Scholar 

  22. Nobbenhuis M, Walboomers JM, Helmerhorst TJ et al. (1999) Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20–25

    Article  PubMed  CAS  Google Scholar 

  23. Parkin DM, Bray FI, Deves SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37: 4–66

    Article  Google Scholar 

  24. Petry K-U, Menton S, Loenen-Frosch F van et al. (2003) Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: Results for 8466 patients. Br J Cancer 88: 1570–1577

    Article  PubMed  Google Scholar 

  25. Schiffman M, Solomon D (2003) Findings to date from the ASCUS-LSIL Triage study (ALTS). Arch Pathol Lab Med 127: 946–949

    PubMed  Google Scholar 

  26. Schneider A, Meinhardt G, Villiers EM de, Gissmann L (1987) Sensitivity of the cytologic diagnosis of cervical condyloma in comparison with HPV DNA hybridization studies. Diagn Cytopathol 3: 250–255

    Article  PubMed  CAS  Google Scholar 

  27. Schneider A, Hoyer H, Lotz B et al. (2000) Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 89: 529–534

    Article  PubMed  CAS  Google Scholar 

  28. Speich N, Schmitt C, Bollmann R, Bollmann M (2004) Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: Genotype spectrum of patients from the west German area. J Med Microbiol 53: 1–4

    Article  CAS  Google Scholar 

  29. Vizcaino AP, Moreno V, Bosch FX et al. (2000) International trends in the incidence of cervical cancer: II Squamous cell carcinoma. Int J Cancer 86: 429–435

    Article  PubMed  CAS  Google Scholar 

  30. Walboomers JMM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 1–3

    Article  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Referententätigkeit für Fa. Cytyc im Jahr 2005.

Author information

Authors and Affiliations

  1. Institut für Pathologie, Heilsbachstraße 15, 53123, Bonn, Deutschland

    R. Bollmann, A.D. Varnai & M. Bollmann

  2. Institut für Pathologie und Neuropathologie, Universitätsklinikum Essen, Essen, Deutschland

    A. Bankfalvi

Authors
  1. R. Bollmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.D. Varnai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Bankfalvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Bollmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Bollmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bollmann, R., Varnai, A., Bankfalvi, A. et al. Risikoadaptierte multimodale gynäkozytologische Krebsvorsorge. Pathologe 28, 334–338 (2007). https://doi.org/10.1007/s00292-007-0923-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-007-0923-9

Schlüsselwörter

Keywords

Search

Navigation